Piramal Pharma (PPLPHARMA) Q1 24/25 earnings summary

Executive summary

• Q1 FY25 revenue grew 12% year-over-year to ₹1,951 Cr, led by 18% growth in CDMO and double-digit growth in India consumer healthcare; EBITDA rose 31% to ₹224 Cr, with margin improving to 11% from 10% in Q1 FY24, driven by cost optimization and operational efficiencies.

• All three business segments—CDMO, CHG, and ICH—delivered positive revenue growth, with CDMO leading at 18% YoY.

• Net debt-to-EBITDA ratio improved to 2.8x from 5x a year ago, reflecting deleveraging efforts.

• Maintained a strong compliance record, with successful US FDA inspections and no OAI since 2011.

• Recognized as a top sustainable organization in India.

Financial highlights

• CDMO business contributed significantly, with innovation-related work now at 50% of CDMO revenues, up from 35% five years ago.

• Generic API business saw a demand pickup.

• Complex hospital generics experienced strong demand but faced price erosion in the US, offsetting volume growth.

• Power brands in consumer healthcare grew 19% and now account for 48% of segment sales; e-commerce sales in consumer healthcare grew 37% year-over-year, now 19% of segment sales.

• PAT loss narrowed to ₹89 Cr from ₹99 Cr YoY; PAT margin improved to -5% from -6%.

Outlook and guidance

• FY25 guidance reiterated: early teens year-over-year growth in revenue and absolute EBITDA, with a meaningful margin increase.

• No upgrade to guidance despite strong order book; focus remains on balancing quarterly performance.

• Capacity expansion and portfolio development ongoing in CHG and ICH to meet demand and drive growth.

• Regulatory changes and supply chain diversification expected to provide medium- to long-term opportunities.

• Early signs of improvement in biotech funding for CDMO; further quarters needed to confirm recovery.